



Jim Doyle
Governor

Karen E. Timberlake
Secretary

State of Wisconsin
Department of Health Services

Telephone: 608-266-8922
FAX: 608-266-1096
TTY: 888-692-1402
dhs.wisconsin.gov

MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
August 19, 2009

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Catherine Decker PharmD	Yes
3	Bradley Fedderly, M.D.	Yes
4	Lawrence Fleming, M.D.	No
5	Shel Gross	Yes
6	Kevin Izard, M.D.	Yes
7	Steve Maike, RPh	Yes
8	Pat Towers	Yes
9	Alicia Walker, PharmD	Yes
10	Michael Witkovsky, M.D.	No
11	Ron Diamond, MD	Yes
12	James Boblin, M.D.	Yes
13	Anthony DeFranco, M.D., FACC	No
14	Ward Brown, M.D.	No

Drug Classes for Review

- ANTIPSYCHOTICS (Bipolar Disease and Schizophrenia)
- ANTIDEPRESSANTS, OTHER (Depression)
- ANTIDEPRESSANTS, SSRIs (Depression)
- STIMULANTS AND RELATED AGENTS (ADD and ADHD)
- ANTIPARKINSON'S AGENTS (Antiparkinsons Disease)
- ALZHEIMER'S AGENTS (Alzheimer's Disease)
- ANALGESICS/ANESTHETICS, TOPICAL (Topical Pain Relief)
- NSAIDS (Inflammation and Pain)
- ANTIHYPERURICEMICS (Gout)**
- CYTOKINE AND CAM ANTAGONISTS (Rheumatoid Arthritis and Psoriasis)
- ANDROGENIC AGENTS (Male Hormones)
- BONE RESORPTION SUPPRESSION AND RELATED AGENTS (Osteoporosis)
- PANCREATIC ENZYMES (Digestive enzymes, pancreatitis, cystic fibrosis)
- HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS (Diabetes)

HYPOGLYCEMICS, INSULIN (Diabetes)
 ANTIEMETICS (Nausea and Vomiting)
 ANTIBIOTICS, VAGINAL (Bacterial Vaginosis)
 CEPHALOSPORINS AND RELATED ANTIBIOTICS (Infections)
 FLUOROQUINOLONES, ORAL (Infections)
 MACROLIDES/KETOLIDES (Infections)
TETRACYCLINES (Infections)
 ANTIFUNGALS, ORAL (Nail and other fungal infections)
 ANTIVIRALS, ORAL (Flu/Herpes)
 ANTIFUNGALS, TOPICAL (Skin fungal infections)
 ANTIPARASITICS, TOPICAL (Treatment of topical parasites)
 ANTIVIRALS, TOPICAL (Herpes)
 STEROIDS, TOPICAL LOW (Skin disorders, psoriasis, eczema)
 STEROIDS, TOPICAL MEDIUM (Skin disorders, psoriasis, eczema)
 STEROIDS, TOPICAL HIGH (Skin disorders, psoriasis, eczema)
 STEROIDS, TOPICAL VERY HIGH (Skin disorders, psoriasis, eczema)
 ATOPIC DERMATITIS (Eczema)
 HEPATITIS B AGENTS (Hepatitis B)
 BRONCHODILATORS, ANTICHOLINERGIC (Emphysema)
 BRONCHODILATORS, BETA AGONIST (Asthma)
 GLUCOCORTICOIDS, INHALED (Asthma)
 INTRANASAL RHINITIS AGENTS (Allergies)
 LEUKOTRIENE MODIFIERS (Asthma)
 PLATELET AGGREGATION INHIBITORS (Prevention of blood clots)
 OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS (Eye allergies and infections)
 OPHTHALMICS, ANTIBIOTICS (Eye infections)
 OPHTHALMIC, ANTIFLAMMATORIES (Pain and Inflammation of the eye)
 OPHTHALMICS, GLAUCOMA AGENTS (Glaucoma)

1. ANTIPSYCHOTICS (Bipolar Disease and Schizophrenia)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
FLUPHENAZINE (ORAL)	0.8%	NR	YES-GENERIC		
THIOTHIXENE (ORAL)	0.6%	NR	YES-GENERIC		
AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.2%	NR	YES-GENERIC		
THIORIDAZINE (ORAL)	0.4%	NR	YES-GENERIC		
HALOPERIDOL (ORAL)	3.1%	NR	YES-GENERIC		
CHLORPROMAZINE (ORAL)	0.8%	NR	YES-GENERIC		
TRIFLUOPERAZINE (ORAL)	0.3%	NR	YES-GENERIC		

1. ANTIPSYCHOTICS (Bipolar Disease and Schizophrenia)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
MOBAN (ORAL)	0.0%	NR	YES		
PERPHENAZINE (ORAL)	0.4%	NR	YES-GENERIC		
RISPERIDONE (ORAL)	24.3%	ON	YES-GENERIC		
CLOZAPINE (ORAL)	3.2%	ON	YES-GENERIC		
FAZACLO (ORAL)	0.2%	OFF	NO		
GEODON (ORAL)	10.1%	ON	YES		
SEROQUEL (ORAL)	28.9%	ON	YES		
SYMBYAX (ORAL)	0.1%	OFF	NO		
SEROQUEL XR (ORAL)	0.7%	OFF	NO		
INVEGA (ORAL)	1.1%	OFF	NO		
ABILIFY (ORAL)	15.8%	OFF	NO		
ZYPREXA (ORAL)	7.8%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - James Boblin
 - All members were in favor of the motion.

2. ANTIDEPRESSANTS, OTHER (Depression)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
TRAZODONE (ORAL)	26.1%	ON	YES-GENERIC		
MIRTAZAPINE (ORAL)	12.9%	ON	YES-GENERIC		
BUPROPION (ORAL)	1.7%	ON	YES-GENERIC		
MARPLAN (ORAL)	0.0%	NR	YES		
VENLAFAXINE (ORAL)	2.3%	ON	YES-GENERIC		
NARDIL (ORAL)	0.0%	NR	YES		
BUPROPION SR (ORAL)	13.8%	ON	YES-GENERIC		
PARNATE (ORAL)	0.0%	NR	NO		YES
NEFAZODONE (ORAL)	0.3%	OFF	NO-GENERIC		
VENLAFAXINE ER (ORAL)	0.0%	NR	NO		
BUPROPION XL (ORAL)	10.1%	ON	YES-GENERIC		
EFFEXOR XR (ORAL)	21.1%	ON	YES		
PRISTIQ (ORAL)	0.5%	OFF	NO		
CYMBALTA (ORAL)	10.7%	OFF	NO		

2. ANTIDEPRESSANTS, OTHER (Depression)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
TRANLYCYPROMINE SULFATE (ORAL)	0.0%	NR	NO-GENERIC		YES
APLENZIN (ORAL)	0.0%	NR	NO		
EMSAM (TRANSDERMAL)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Bradley Fedderly
 - Second - Ron Diamond
 - All members were in favor of the motion.

3. ANTIDEPRESSANTS, SSRIs (Depression)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
CITALOPRAM (ORAL)	24.5%	ON	YES-GENERIC		
SERTRALINE (ORAL)	26.8%	ON	YES-GENERIC		
FLUOXETINE (ORAL)	27.3%	ON	YES-GENERIC		
PAROXETINE (ORAL)	11.8%	ON	YES-GENERIC		
LEXAPRO (ORAL)	8.4%	OFF	NO		
PEXEVA (ORAL)	0.0%	OFF	NO		
PROZAC WEEKLY (ORAL)	0.1%	OFF	NO		
FLUVOXAMINE (ORAL)	0.8%	ON	YES-GENERIC		
PAROXETINE CR (ORAL)	0.3%	OFF	NO-GENERIC		
LUVOX CR (ORAL)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Shel Gross
 - Second – Kevin Izard
 - All members were in favor of the motion.

4. STIMULANTS AND RELATED AGENTS (ADD and ADHD)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
AMPHETAMINE SALT COMBO (ORAL)	14.3%	ON	YES-GENERIC		
METHYLPHENIDATE (ORAL)	9.5%	ON	YES-GENERIC		
METHYLPHENIDATE ER (ORAL)	2.2%	ON	YES-GENERIC		
METADATE CD (ORAL)	2.7%	ON	YES		
DEXMETHYLPHENIDATE (ORAL)	0.7%	ON	YES-GENERIC		

4. STIMULANTS AND RELATED AGENTS (ADD and ADHD)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
VYVANSE (ORAL)	8.1%	ON	YES		
FOCALIN XR (ORAL)	4.9%	ON	YES		
DAYTRANA (TRANSDERMAL)	1.3%	OFF	YES		
DESOXYN (ORAL)	0.0%	OFF	NO		
CONCERTA (ORAL)	18.1%	ON	YES		
DESTROAMPHETAMINE (ORAL)	3.1%	ON	YES-GENERIC		
RITALIN LA (ORAL)	1.2%	OFF	NO		
ADDERALL XR (ORAL)	27.0%	ON	YES		
STRATTERA (ORAL)	5.6%	OFF	NO		
PROCENTRA (ORAL)	0.0%	NR	NO		
PROVIGIL (ORAL)	1.0%	OFF	NO		
AMPHETAMINE SALT COMBO ER (ORAL)	0.0%	OFF	NO-GENERIC		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Bradley Fedderly
 - Second – Pat Towers
 - All members were in favor of the motion.

5. ANTIPARKINSONS AGENTS (Antiparkinsons Disease)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
BENZTROPINE (ORAL)	34.8%	ON	YES-GENERIC		
TRIHEXYPHENIDYL (ORAL)	6.1%	ON	YES-GENERIC		
SELEGILINE (ORAL)	0.4%	ON	YES-GENERIC		
CARBINDOPA / LEVODOPA (ORAL)	22.2%	ON	YES-GENERIC		
ROPINIROLE (ORAL)	22.7%	ON	YES-GENERIC		
REQUIP XL (ORAL)	0.3%	OFF	NO	YES	
MIRAPEX (ORAL)	9.9%	OFF	NO		
CARBINDOPA / LEVODOPA ODT (ORAL)	0.2%	ON	YES-GENERIC		
BROMOCRIPTINE (ORAL)	1.0%	ON	YES-GENERIC		
COMTAN (ORAL)	0.5%	OFF	NO		
STALEVO (ORAL)	1.2%	ON	YES		
ZELAPAR (ORAL)	0.0%	OFF	NO		
AZILECT (ORAL)	0.2%	OFF	NO		
TASMAR (ORAL)	0.0%	OFF	NO		

- Dr. James Boblin made a motion to add Requip XL as a preferred agent with a diagnosis restriction of Parkinson’s Disease
 - Second - Bradley Fedderly
 - All members were in favor of the motion.

6. <i>Alzheimers Agents (Alzheimer’s Disease)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ARICEPT / ARICEPT ODT (ORAL)	57.3%	ON	YES		
GALANTAMINE (ORAL)	2.4%	ON	YES-GENERIC		
EXELON (TRANSDERM.)	2.1%	OFF	YES		
EXELON (ORAL)	3.0%	ON	YES		
NAMENDA (ORAL)	33.5%	ON	YES		
GALANTAMINE ER (ORAL)	1.8%	ON	YES-GENERIC		
RAZADYNE SOLUTION (ORAL)	0.0%	NR	NO		
EXELON SOLUTION (ORAL)	0.0%	OFF	NO		
COGNEX (ORAL)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - Bradley Fedderly
 - All members were in favor of the motion.

7. <i>ANALGESICS-ANESTHETICS, TOPICAL (Topical Pain Relief)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
VOLTAREN (TOPICAL)	13.7%	ON	YES		
LIDODERM (TOPICAL)	83.7%	ON	YES		
FLECTOR (TOPICAL)	2.5%	OFF	NO	YES	NO

- Dr. James Boblin made a motion to approve staff recommendations and add Flector patch as a preferred agent.
 - Second - Catherine Decker
 - Alicia Walker and Kevin Izard were opposed to the motion, but all others were in favor. The motion passes.

8. <i>NSAIDS (Inflammation and Pain)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
PIROXICAM (ORAL)	2.2%	ON	YES-GENERIC		

8. NSAIDS (Inflammation and Pain)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
IBUPROFEN RX (ORAL)	47.6%	ON	YES-GENERIC		
MELOXICAM (ORAL)	5.2%	ON	YES-GENERIC		
KETOROLAC (ORAL)	1.7%	ON	YES-GENERIC		
NAPROXEN RX (ORAL)	20.2%	ON	YES-GENERIC		
IBUPROFEN OTC (ORAL)	0.0%	NR	YES-GENERIC		
FLURBIPROFEN (ORAL)	0.1%	ON	YES-GENERIC		
KETOPROFEN (ORAL)	0.5%	ON	YES-GENERIC		
OXAPROZIN (ORAL)	0.1%	OFF	NO-GENERIC		
DICLOFENAC (ORAL)	7.7%	ON	YES-GENERIC		
SULINDAC (ORAL)	0.2%	OFF	NO-GENERIC		
ETODOLAC (ORAL)	0.4%	OFF	NO-GENERIC		
INDOMETHACIN (ORAL/RECTAL)	2.5%	ON	YES-GENERIC		
NABUMETONE (ORAL)	4.5%	ON	YES-GENERIC		
FENOPROFEN (ORAL)	0.0%	OFF	NO-GENERIC		
ARTHROTEC (ORAL)	0.4%	OFF	NO		
CELEBREX (ORAL)	6.6%	ON	NO		
MECLOFENAMATE (ORAL)	0.0%	ON	YES-GENERIC		
TOLMETIN (ORAL)	0.0%	OFF	NO-GENERIC		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - Kevin Izard
 - All members were in favor of the motion.

9. ANTIHYPERURICEMICS (Gout)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ALLOPURINOL (ORAL)	78.7%	NA	YES-GENERIC		
COLCHICINE (ORAL)	18.1%	NA	YES-GENERIC		
PROBENECID (ORAL)	1.9%	NA	YES-GENERIC		
PROBENECID / COLCHICINE (ORAL)	1.2%	NA	YES-GENERIC		
ULORIC (ORAL)	0.0%	NA	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Bradley Fedderly
 - Second - Kevin Izard
 - All members were in favor of the motion.

- o James Boblin was not present for the vote.

<i>10. CYTOKINE AND CAM ANTAGONISTS (Rheumatoid Arthritis and Psoriasis)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
KINERET (INJECTION)	1.4%	ON	YES		
CIMZIA (INJECTION)	0.4%	NR	YES		
HUMIRA (INJECTION)	50.5%	ON	YES		
ENBREL (INJECTION)	47.6%	ON	YES		

- The Committee made a motion to approve staff recommendations as presented.
 - o Motion – Kevin IZard
 - o Second - Bradley Fedderly
 - o All members were in favor of the motion.

<i>11. ANDROGENIC AGENTS (Male Hormones)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ANDRODERM (TRANSDERM.)	23.0%	ON	YES		
ANDROGEL (TRANSDERM.)	74.1%	ON	YES		
TESTIM (TRANSDERM.)	2.8%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - o Motion – James Boblin
 - o Second - Catherine Decker
 - o All members were in favor of the motion.

<i>12. BONE RESORPTION SUPPRESSION AND RELATED AGENTS (Osteoporosis)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
MIACALCIN (NASAL)	1.7%	OFF	YES		
ALENDRONATE TABLETS (ORAL)	74.2%	ON	YES-GENERIC		
ACTONEL (ORAL)	4.7%	OFF	NO		
BONIVA (ORAL)	3.6%	OFF	NO		
EVISTA (ORAL)	4.2%	OFF	NO		
FORTICAL (NASAL)	0.2%	ON	NO		
DIDRONEL (ORAL)	0.0%	OFF	NO		
FOSAMAX PLUS D (ORAL)	8.6%	ON	NO		

**12. BONE RESORPTION SUPPRESSION AND RELATED AGENTS
(Osteoporosis)**

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
CALCITONIN SALMON (NASAL)	2.6%	ON	NO-GENERIC		
FOSAMAX SOLUTION (ORAL)	0.2%	ON	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin IZard
 - Second - Bradley Fedderly
 - All members were in favor of the motion.

13. PANCREATIC ENZYMES (Digestive enzymes, pancreatitis, cystic fibrosis)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
VIOKASE (ORAL)	12.1%	ON	YES		
PANCRELIPASE (ORAL)	30.9%	ON	YES-GENERIC		
PANCREASE MT (ORAL)	14.5%	ON	YES		
CREON (ORAL)	27.0%	ON	YES		
ULTRASE (ORAL)	11.5%	ON	NO	YES	YES with no restrictions
PANCRECARB MD (ORAL)	3.9%	OFF	NO		

- Catherine Decker made a motion to accept staff recommendations as presented and add Ultrase as a preferred agent with a diagnosis restriction for cystic fibrosis.
 - Second - Bradley Fedderly
 - All members were in favor of the motion.

14. HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS (Diabetes)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
JANUMET (ORAL)	10.5%	ON	YES		
JANUVIA (ORAL)	64.6%	ON	YES		
SYMLIN (SUBCUTANE.)	0.2%	ON	NO		
BYETTA PENS (SUBCUTANE.)	24.2%	ON	NO		
SYMLIN PENS (SUBCUTANE.)	0.5%	ON	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - Bradley Fedderly

- Rosanne Barber opposed the motion but all other members were in favor of the motion. The motion passes.

<i>15. HYPOGLYCEMICS, INSULIN AND RELATED AGENTS (Diabetes)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
HUMALOG (SUBCUTANE.)	17.6%	ON	YES		
HUMULIN (SUBCUTANE.)	18.9%	ON	YES		
HUMALOG MIX (SUBCUTANE.)	2.5%	ON	YES		
NOVOLIN PENS (SUBCUTANE.)	0.4%	OFF	NO		
NOVOLIN (SUBCUTANE.)	0.4%	OFF	NO		
LANTUS (SUBCUTANE.)	27.2%	ON	YES		
HUMALOG PENS (SUBCUTANE.)	10.6%	ON	YES		
NOVOLOG (SUBCUTANE.)	1.3%	OFF	NO		
LEVEMIR (SUBCUTANE.)	1.8%	ON	NO		
HUMALOG MIX PENS (SUBCUTANE.)	2.4%	ON	YES		
NOVOLOG MIX 70/30 (SUBCUTANE.)	0.4%	OFF	NO		
HUMULIN PENS (SUBCUTANE.)	1.8%	ON	YES		
NOVOLOG PENS (SUBCUTANE.)	1.3%	OFF	NO		
NOVOLOG MIX (SUBCUTANE.)	0.2%	OFF	NO		
LANTUS PENS (SUBCUTANE.)	10.5%	ON	YES		
LEVEMIR PENS (SUBCUTANE.)	2.5%	ON	NO		
APIDRA (SUBCUTANE.)	0.1%	OFF	NO		
APIDRA PENS (SUBCUTANE.)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – James Boblin
 - Second - Catherine Decker
 - All members were in favor of the motion.

<i>16. ANTIEMETICS (Nausea and Vomiting)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
MARINOL (ORAL)	0.4%	NR	NO		
ONDANSETRON / ODT (ORAL)	95.3%	ON	YES-GENERIC		

16. ANTIEMETICS (Nausea and Vomiting)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
SANCUSO (TRANSDERMAL)	0.0%	NR	NO	YES	
EMEND (ORAL)	2.1%	ON	YES		
CESAMET (ORAL)	0.0%	OFF	NO		
GRANISETRON (ORAL)	0.4%	ON	NO-GENERIC		
AMZEMET (ORAL)	0.0%	OFF	NO		
DRONABINOL (ORAL)	1.7%	OFF	NO-GENERIC		

- Dr. Brad Fedderly made a motion to accept staff recommendations, add old generics to PDL Quick Reference and add Sancuso as a preferred agent. The motion also included a request for staff to report utilization data for Sancuso for 6 months to the PA Committee at their next meeting.
 - Motion – Bradley Fedderly
 - Second - Alicia Walker
 - All members were in favor of the motion.
 - Ron Diamond was not in the room at the time of the vote.

17. ANTIBIOTICS, VAGINAL (Bacterial Vaginosis)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
CLINDAMYCIN (VAGINAL)	7.6%	ON	YES-GENERIC		
VANDAZOLE (VAGINAL)	12.1%	NR	YES		
METRONIDAZOLE (VAGINAL)	61.7%	ON	YES-GENERIC		
CLEOCIN OVULES (VAGINAL)	5.4%	ON	YES		
CLINDESSE (VAGINAL)	13.2%	ON	YES		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - James Boblin
 - All members were in favor of the motion.

18. CEPHALOSPORINS AND RELATED ANTIBIOTICS (Infections)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
CEPHALEXIN (ORAL)	24.4%	ON	YES-GENERIC		

18. CEPHALOSPORINS AND RELATED ANTIBIOTICS (Infections)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
AUGMENTIN 125 SUSPENSION (ORAL)	0.1%	NR	YES		
AMOXICILLIN/CLAV TABLET (ORAL)	23.1%	ON	YES-GENERIC		
CEFACLOR (ORAL)	0.6%	ON	YES-GENERIC		
CEFADROXIL (ORAL)	1.6%	ON	YES-GENERIC		
AMOXICILLIN/CLAV SUSPENSION (ORAL)	21.3%	ON	YES-GENERIC		
SUPRAX (ORAL)	0.8%	ON	YES		
CEFUROXIME (ORAL)	4.8%	ON	YES-GENERIC		
AUGMENTIN 250 SUSPENSION (ORAL)	0.9%	NR	YES		
CEFPROZIL (ORAL)	4.2%	ON	YES-GENERIC		
CEFDINIR (ORAL)	17.5%	ON	YES-GENERIC		
SPECTRACEF (ORAL)	0.0%	OFF	NO		
CEFTIN (ORAL)	0.1%	NR	NO		
CEFPODOXIME (ORAL)	0.4%	ON	YES-GENERIC		
AUGMENTIN XR (ORAL)	0.0%	OFF	NO		
CEDAX (ORAL)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin Izard
 - Second - Alicia Walker
 - All members were in favor of the motion.

19. FLUOROQUINOLONES, ORAL (Infections)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
CIPROFLOXACIN TABLETS (ORAL)	51.9%	ON	YES-GENERIC		
NOROXIN (ORAL)	0.1%	OFF	NO		
AVELOX (ORAL)	5.1%	ON	YES		
LEVAQUIN (ORAL)	42.5%	ON	NO		
CIPROFLOXACIN ER (ORAL)	0.0%	OFF	NO-GENERIC		
PROQUIN XR (ORAL)	0.0%	OFF	NO		
FACTIVE (ORAL)	0.0%	OFF	NO		
CIPRO SUSPENSION (ORAL)	0.3%	OFF	NO		
OFLOXACIN (ORAL)	0.2%	ON	NO-GENERIC		

- The Committee made motion #1 to approve staff recommendations and add Levaquin as a preferred agent.
 - Motion #1 – Kevin Izard
 - Second - James Boblin
 - The motion failed 2-7.
 - Ron Diamond was not present for the vote.

- The Committee made a second motion to approve staff recommendations as presented.
 - Motion #2 - Brad Fedderly
 - Second – James Boblin
 - The motion passed 8-1.
 - Ron Diamond was not present for the vote.

20. <i>MACROLIDES-KETOLIDES (Infections)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ERYTHROMYCIN (ORAL)	1.0%	ON	YES-GENERIC		
AZITHROMYCIN (ORAL)	95.2%	ON	YES-GENERIC		
CLARITHROMYCIN (ORAL)	3.8%	ON	YES-GENERIC		
ZMAX (ORAL)	0.0%	OFF	NO		
KETEK (ORAL)	0.0%	OFF	NO		
CLARITHROMYCIN ER (ORAL)	0.0%	OFF	NO-GENERIC		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Bradley Fedderly
 - Second - Kevin Izard
 - All members were in favor of the motion.

21. <i>TETRACYCLINES (Infections)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
TETRACYCLINE (ORAL)	13.3%	NA	YES-GENERIC		
DOXYCYCLINE (ORAL)	63.9%	NA	YES-GENERIC		
MINOCYCLINE (ORAL)	21.7%	NA	YES-GENERIC		
NUTRIDOX (ORAL)	0.0%	NA	NO		
ORACEA (ORAL)	0.2%	NA	NO		
SOLODYN (ORAL)	0.4%	NA	NO		
ADOXA TT (ORAL)	0.0%	NA	NO		
ADOXA CK (ORAL)	0.0%	NA	NO		

21. TETRACYCLINES (Infections)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
DEMECLOCYCLINE (ORAL)	0.5%	NA	NO-GENERIC		YES

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Shel Gross
 - Second - Pat Towers
 - All members were in favor of the motion.

22. ANTI-FUNGALS, ORAL (Nail and other fungal infections)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ANCOBON (ORAL)	0.0%	OFF	YES		
FLUCONAZOLE (ORAL)	62.7%	ON	YES-GENERIC		
KETOCONAZOLE (ORAL)	1.7%	ON	YES-GENERIC		
TERBINAFINE (ORAL)	3.8%	ON	YES-GENERIC		
NYSTATIN (ORAL)	20.7%	ON	YES-GENERIC		
GRIS-PEG (ORAL)	1.4%	ON	YES		
CLOTRIMAZOLE (MECOUS MEM)	1.7%	ON	NO-GENERIC		
GRISEOFULVIN SUSPENSION (ORAL)	7.3%	ON	YES-GENERIC		
GRIFULVIN V TABLETS (ORAL)	0.1%	OFF	NO		
LAMISIL GRANULES (ORAL)	0.0%	OFF	NO		
ITRACONAZOLE (ORAL)	0.3%	ON	YES-GENERIC		
VFEND (ORAL)	0.4%	ON	NO		Grandfather
NOXAFIL (ORAL)	0.1%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - Rosanne Barber
 - The motion passed 5-4.

23. ANTI-VIRALS, ORAL (Flu/Herpes)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ACYCLOVIR (ORAL)	22.4%	ON	YES-GENERIC		
AMANTADINE (ORAL)	6.0%	ON	YES-GENERIC		
RIMANTADINE (ORAL)	0.5%	ON	YES-GENERIC		

23. ANTI-VIRALS, ORAL (Flu/Herpes)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
FAMVIR (ORAL)	0.0%	OFF	YES		
RELENZA (INHALATION)	2.9%	ON	YES		
TAMIFLU (ORAL)	8.5%	ON	YES		
VALTREX (ORAL)	58.1%	ON	YES		
FAMCICLOVIR (ORAL)	1.6%	ON	NO-GENERIC		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin Izard
 - Second – James Boblin
 - All members were in favor of the motion.

24. ANTI-FUNGALS, TOPICAL (Skin fungal infections)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
TOLNAFTATE OTC (TOPICAL)	0.3%	NR	YES-GENERIC		
NYSTATIN-TRIAMCINOLONE (TOPICAL)	6.7%	ON	YES-GENERIC		
MICONAZOLE OTC (TOPICAL)	2.7%	NR	YES-GENERIC		
CLOTRIMAZOLE OTC (TOPICAL)	5.7%	NR	YES-GENERIC		
NYSTATIN (TOPICAL)	33.8%	ON	YES-GENERIC		
CLOTRIMAZOLE RX (TOPICAL)	11.8%	NR	YES-GENERIC		
TERBINAFINE OTC (TOPICAL)	1.9%	NR	YES-GENERIC		
CLOTRIMAZOLE-BETAMETHASONE (TOPICAL)	11.9%	ON	YES-GENERIC		
ECONAZOLE (TOPICAL)	2.8%	ON	YES-GENERIC		
CICLOPIROX SOLUTION (TOPICAL)	0.8%	ON	NO-GENERIC		
KETOCONAZOLE (TOPICAL)	11.3%	ON	YES-GENERIC		
XOLEGEL (TOPICAL)	0.0%	OFF	NO		
NAFTIN (TOPICAL)	0.1%	OFF	NO		
KETOCONAZOLE SHAMPOO (TOPICAL)	9.9%	ON	YES-GENERIC		
CICLOPIROX CR / SUSP / GEL (TOPICAL)	0.1%	OFF	NO-GENERIC		
OXISTAT (TOPICAL)	0.1%	OFF	NO		
LOPROX SHAMPOO (TOPICAL)	0.0%	OFF	NO		
MENTAX (TOPICAL)	0.0%	OFF	NO		
ERTACZO (TOPICAL)	0.0%	OFF	NO		
VUSION (TOPICAL)	0.1%	OFF	NO		

24. ANTI-FUNGALS, TOPICAL (Skin fungal infections)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
EXTINA (TOPICAL)	0.0%	OFF	NO		
CNL 8 (TOPICAL)	0.0%	OFF	NO		
BENSAL HP (TOPICAL)	0.0%	NR	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin Izard
 - Second - James Boblin
 - Brad Fedderly opposed the motion. All other members were in favor of the motion. The motion passes.

25. ANTI-PARASITICS, TOPICAL (Treatment of topical parasites)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
PERMETHRIN OTC (TOPICAL)	16.7%	ON	YES-GENERIC		
PERMETHRIN (TOPICAL)	72.2%	ON	YES-GENERIC		
EURAX (TOPICAL)	1.7%	ON	YES		
OVIDE (TOPICAL)	9.3%	ON	YES		
LINDANE (TOPICAL)	0.2%	OFF	NO-GENERIC		
MALATHION (TOPICAL)	0.0%	NR	NO-GENERIC		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin Izard
 - Second - Catherine Decker
 - All members were in favor of the motion.

26. ANTI-VIRALS, TOPICAL (Herpes)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
DENAVIR (TOPICAL)	22.9%	ON	YES		
ZOVIRAX OINTMENT (TOPICAL)	59.9%	ON	YES		
ZOVIRAX CREAM (TOPICAL)	17.2%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – James Boblin
 - Second - Rosanne Barber
 - All members were in favor of the motion.

27. STEROIDS, TOPICAL LOW (Skin disorders, psoriasis, eczema)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
HYDROCORTISONE (TOPICAL)	80.8%	ON	YES-GENERIC		
DESONIDE (TOPICAL)	19.0%	ON	YES-GENERIC		
ALCLOMETASONE DIPROPIONATE (TOPICAL)	0.2%	OFF	NO-GENERIC		
VERDES0 (TOPICAL)	0.0%	OFF	NO		
DESONATE (TOPICAL)	0.1%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – James Boblin
 - Second – Kevin Izard
 - All members were in favor of the motion.

28. STEROIDS, TOPICAL MEDIUM (Skin disorders, psoriasis, eczema)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
LUXIQ (TOPICAL)	1.6%	ON	YES		
HYDROCORTISONE VALERATE (TOPICAL)	25.1%	ON	YES-GENERIC		
FLUTICASONE PROPIONATE (TOPICAL)	24.4%	ON	YES-GENERIC		
MOMETASONE FUROATE (TOPICAL)	40.5%	ON	YES-GENERIC		
HYDROCORTISONE BUTYRATE (TOPICAL)	2.7%	ON	YES-GENERIC		
PREDNICARBATE (TOPICAL)	0.1%	OFF	NO-GENERIC		
CORDAN TAPE (TOPICAL)	0.5%	OFF	NO		
LOCIOD LIPOCREAM (TOPICAL)	5.0%	ON	NO		
CLODERM (TOPICAL)	0.2%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - Catherine Decker
 - All members were in favor of the motion.

29. STEROIDS, TOPICAL HIGH (Skin disorders, psoriasis, eczema)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
CAPEX SHAMPOO (TOPICAL)	0.4%	ON	YES		

29. *STEROIDS, TOPICAL HIGH (Skin disorders, psoriasis, eczema)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
TRIAMCINOLONE ACETONIDE (TOPICAL)	74.3%	ON	YES-GENERIC		
BETAMETHASONE VALERATE (TOPICAL)	2.5%	ON	YES-GENERIC		
FLUOCINOLONE ACETONIDE (TOPICAL)	3.0%	ON	YES-GENERIC		
FLUOCINONIDE-E (TOPICAL)	0.2%	ON	YES-GENERIC		
FLUOCINONIDE (TOPICAL)	7.7%	ON	YES-GENERIC		
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.1%	ON	YES-GENERIC		
BETAMETHASONE DIPROPIONATE (TOPICAL)	9.5%	ON	YES-GENERIC		
DIFLORASONE DIACETATE (TOPICAL)	0.2%	ON	YES-GENERIC		
DERMA-SMOOTH/FS (TOPICAL)	1.4%	ON	YES		
HALOG (TOPICAL)	0.0%	OFF	NO		
AMCINONIDE (TOPICAL)	0.0%	OFF	NO-GENERIC		
VANOS (TOPICAL)	0.0%	OFF	NO		
DESOXIMETASONE (TOPICAL)	0.7%	OFF	NO-GENERIC		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – James Boblin
 - Second - Rosanne Barber
 - All members were in favor of the motion.

30. *STEROIDS, TOPICAL VERY HIGH (Skin disorders, psoriasis, eczema)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
CLOBETASOL PROPIONATE (TOPICAL)	86.5%	ON	YES-GENERIC		
CLOBETASOL EMOLLIENT (TOPICAL)	4.1%	ON	YES-GENERIC		
HALOBETASOL PROPIONATE (TOPICAL)	7.9%	ON	YES-GENERIC		
CLOBEX (TOPICAL)	1.0%	OFF	NO		
OLUX-E (TOPICAL)	0.2%	OFF	NO		
OLUX-OLUX-E (TOPICAL)	0.2%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – James Boblin
 - Second - Shel Gross
 - All members were in favor of the motion.

31. ATOPIC DERMATITIS (Eczema)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
PROTOPIC (TOPICAL)	33.8%	OFF	NO		
ELIDEL (TOPICAL)	66.2%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Pat Towers
 - Second - Kevin Izard
 - All members were in favor of the motion.

32. HEPATITIS B AGENTS (Hepatitis B)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
EPIVIR HBV (ORAL)	28.3%	ON	YES		
TYZEKA (ORAL)	0.7%	ON	YES		
HEPSERA (ORAL)	26.9%	ON	YES		
BARACLUDGE (ORAL)	44.1%	ON	YES		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – James Boblin
 - Second - Alicia Walker
 - All members were in favor of the motion.

33. BRONCHODILATORS, ANTI-CHOLINERGIC (Emphysema)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
IPRATROPIUM NEBULIZER (INHALATION)	13.1%	ON	YES-GENERIC		
COMBIVENT (INHALATION)	41.3%	ON	YES		
ATROVENT HFA (INHALATION)	4.8%	ON	YES		
IPRATROPIUM / ALBUTEROL (INHALATION)	2.8%	OFF	NO-GENERIC		
SPIRIVA (INHALATION)	38.0%	ON	YES		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Bradley Fedderly
 - Second - Catherine Decker
 - All members were in favor of the motion.

34. BRONCHODILATORS, BETA AGONIST (Asthma)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ALBUTEROL (ORAL)	1.1%	ON	YES-GENERIC		
ALBUTEROL NEBULIZER (INHALATION)	19.3%	ON	YES-GENERIC		
PROAIR HFA INHALER (INHALATION)	26.4%	ON	YES		
VENTOLIN HFA (INHALATION)	18.0%	ON	YES		
XOPENEX HFA (INHALATION)	2.1%	ON	NO		
PROVENTIL HFA (INHALATION)	28.8%	ON	NO		
TERBUTALINE (ORAL)	0.2%	ON	YES-GENERIC		
MAXAIR (INHALATION)	0.5%	ON	NO		
METAPROTERENOL (ORAL)	0.0%	ON	NO-GENERIC		
ALBUTEROL NEBULIZER LOW-DOSE (INHALATION)	1.7%	ON	NO-GENERIC		
FORADIL (INHALATION)	0.2%	ON	YES		
SEREVENT (INHALATION)	0.9%	ON	YES		
XOPENEX (INHALATION)	0.7%	OFF	NO		
BROVANA (INHALATION)	0.0%	OFF	NO		
PERFORMIST (INHALATION)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Catherine Decker
 - Second - Steve Maike
 - All members were in favor of the motion.

35. <i>GLUCOCORTICIODS, INHALED (Asthma)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
AZMACORT (INHALATION)	2.0%	ON	YES		
QVAR (INHALATION)	2.7%	ON	YES		
PULMICORT FLEXHALER (INHALATION)	0.5%	OFF	YES		
AEROBID / AEROBID-M (INHALATION)	0.3%	ON	YES		
FLOVENT / FLOVENT HFA (INHALATION)	21.1%	ON	YES		
ASMANEX (INHALATION)	0.6%	OFF	NO	YES	Age restriction
SYMBICORT (INHALATION)	3.3%	ON	YES		
ADVAIR / ADVAIR HFA (INHALATION)	57.2%	ON	YES		
ALVESCO (INHALATION)	0.0%	NR	NO		

35. <i>GLUCOCORTICIODS, INHALED (Asthma)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
PULMICORT RESPULES (INHALATION)	3.7%	ON	NO		
BUDESONIDE RESPULES (INHALATION)	8.5%	ON	NO-GENERIC		

- The Committee made a motion to accept staff recommendations as presented and add Asmanex as a preferred agent.
 - Motion – Kevin Izard
 - Second - Pat Towers
 - The motion passes 5-4.

36. <i>INTRANASAL RHINITIS AGENTS (Allergies)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ASTELIN (NASAL)	3.6%	ON	YES		
FLUTICASONE (NASAL)	72.2%	ON	YES-GENERIC		
ASTEPRO (NASAL)	0.0%	OFF	YES		
BECONASE AQ (NASAL)	0.1%	OFF	YES		
IPRATROPIUM (NASAL)	2.5%	ON	YES-GENERIC		
NASONEX (NASAL)	3.3%	OFF	YES		
VERAMYST (NASAL)	0.9%	OFF	NO		
NASACORT AQ (NASAL)	14.5%	ON	NO		
PATANASE (NASAL)	0.1%	NR	NO		
FLUNISOLIDE (NASAL)	1.2%	ON	NO-GENERIC	YES	
OMNARIS (NASAL)	0.0%	OFF	NO		
RHINOCORT AQUA (NASAL)	0.9%	OFF	NO		

- The Committee made a motion to approve staff recommendation as presented and add flunisolide as a preferred agent.
 - Motion – Kevin Izard
 - Second - Pat Towers
 - All members were in favor of the motion.

37. <i>LEUKOTRIENE MODIFIERS (Asthma)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications

37. *LEUKOTRIENE MODIFIERS (Asthma)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ACCOLATE (ORAL)	1.5%	ON	YES		
SINGULAIR (ORAL)	98.5%	ON	YES		
ZYFLO (ORAL)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Steve Maike
 - Second - Pat Towers
 - All members in favor of the motion.
 - Kevin Izard was not present for the vote.

38. *PLATELET AGGREGATION INHIBITORS (Prevention of blood clots)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
TICLOPIDINE (ORAL)	0.6%	ON	NO-GENERIC		Grandfather
DIPRIDAMOLE (ORAL)	0.8%	ON	YES-GENERIC		
PLAVIX (ORAL)	92.4%	ON	YES		
AGGRENOX (ORAL)	6.2%	ON	YES		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Bradley Fedderly
 - Second - James Boblin
 - All members were in favor of the motion.

39. *OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS (Eye allergies and infections)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ALREX (OPHTHALMIC)	1.4%	OFF	YES		
KETOTIFEN OTC (OPHTHALMIC)	24.7%	ON	YES-GENERIC		
CROMOLYN SODIUM (OPHTHALMIC)	6.4%	ON	YES-GENERIC		
PATADAY (OPHTHALMIC)	14.5%	ON	YES		
PATANOL (OPHTHALMIC)	43.3%	ON	YES		
ALOCRIL (OPHTHALMIC)	0.0%	OFF	NO		
EMADINE (OPHTHALMIC)	0.0%	OFF	NO		
ELESTAT (OPHTHALMIC)	0.6%	OFF	NO		

39. *OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS (Eye allergies and infections)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
ALOMIDE (OPHTHALMIC)	0.1%	OFF	NO		
OPTIVAR (OPHTHALMIC)	1.4%	OFF	NO		
ACULAR (OPHTHALMIC)	7.4%	OFF	NO		
ALAMAST (OPHTHALMIC)	0.0%	OFF	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin Izard
 - Second - James Boblin
 - All members were in favor of the motion.

40. *OPHTHALMIC ANTIBIOTICS (Eye infections)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
BACITRACIN (OPHTHALMIC)	1.1%	NR	YES-GENERIC		
TOBRAMYCIN (OPHTHALMIC)	8.0%	NR	YES-GENERIC		
ERYTHROMYCIN (OPHTHALMIC)	23.1%	ON	YES-GENERIC		
SULFACETAMIDE (OPHTHALMIC)	8.6%	NR	YES-GENERIC		
GENTAMICIN (OPHTHALMIC)	13.2%	NR	YES-GENERIC		
OFLOXACIN (OPHTHALMIC)	2.7%	ON	YES-GENERIC		
ZYMAR (OPHTHALMIC)	8.6%	ON	YES		
VIGAMOX (OPHTHALMIC)	19.8%	ON	YES		
TOBEX OINTMENT (OPHTHALMIC)	0.8%	NR	YES		
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	11.3%	ON	YES-GENERIC		
AZASITE (OPHTHALMIC)	0.2%	OFF	NO		
TRIPLE ANTIBIOTIC (OPHTHALMIC)	1.3%	NR	YES-GENERIC		
BACITRACIN / POLYMYXIN (OPHTHALMIC)	0.9%	NR	YES-GENERIC		
NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	0.0%	NR	YES-GENERIC		
CILOXAN OINTMENT (OPHTHALMIC)	0.1%	OFF	NO		
QUIXIN (OPHTHALMIC)	0.0%	OFF	NO		
IQUIX (OPHTHALMIC)	0.2%	ON	NO		
NATACYN (OPHTHALMIC)	0.0%	NR	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Bradley Federly

- Second - Kevin Izard
- All members were in favor of the motion.

41. OPTHALMICS, ANTI-IMFLAMMATORIES (Pain and inflammation of the eye)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
LOTEMAX (OPHTHALMIC)	20.1%	NR	YES		
FLUOROMETHOLONE (OPHTHALMIC)	12.1%	NR	YES-GENERIC		
FML FORTE (OPHTHALMIC)	0.3%	NR	YES		
PRED MILD (OPHTHALMIC)	1.7%	NR	YES		
FML S.O.P. (OPHTHALMIC)	2.7%	NR	YES		
FLURBIPROFEN (OPHTHALMIC)	0.1%	ON	YES-GENERIC		
DEXAMETHASONE (OPHTHALMIC)	1.4%	NR	YES-GENERIC		
MAXIDEX (OPHTHALMIC)	0.1%	NR	YES		
FLAREX (OPHTHALMIC)	0.8%	NR	YES		
DICLOFENAC (OPHTHALMIC)	0.4%	OFF	YES-GENERIC		
VEXOL (OPHTHALMIC)	1.1%	NR	NO		
ACULAR PF (OPHTHALMIC)	0.4%	ON	NO		
ACULAR LS (OPHTHALMIC)	38.3%	ON	NO		
XIBROM (OPHTHALMIC)	11.7%	ON	NO		
NEVANAC (OPHTHALMIC)	8.6%	ON	NO		
DUREZOL (OPHTHALMIC)	0.1%	NR	NO		
TRIESENCE (INTRAOCULR)	0.1%	NR	NO		
RETISERT (INTRAOCULR)	0.1%	NR	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin Izard
 - Second - Rosanne Barber
 - All members were in favor of the motion.

42. OPTHALMICS, GLAUCOMA AGENTS (Glaucoma)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
COSOPT (OPHTHALMIC)	0.3%	NR	YES		
TRUSOPT (OPHTHALMIC)	0.1%	NR	YES		
BETIMOL (OPHTHALMIC)	1.6%	ON	YES		
PROPINE (OPHTHALMIC)	0.0%	NR	YES		
DIPIVEFRIN (OPHTHALMIC)	0.1%	ON	YES-GENERIC		
LEVOBUNOLOL	1.4%	ON	YES-GENERIC		

42. *OPHTHALMICS, GLAUCOMA AGENTS (Glaucoma)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	State Modifications
(OPHTHALMIC)					
PILOCARPINE (OPHTHALMIC)	1.5%	ON	YES-GENERIC		
BETAXOLOL (OPHTHALMIC)	0.2%	ON	YES-GENERIC		
CARTEOLOL (OPHTHALMIC)	0.3%	ON	YES-GENERIC		
TIMOLOL (OPHTHALMIC)	14.0%	ON	YES-GENERIC		
BRIMONIDINE (OPHTHALMIC)	1.9%	ON	YES-GENERIC		
METIPRANOLOL (OPHTHALMIC)	0.1%	ON	YES-GENERIC		
TRAVATAN / TRAVATAN Z 2.5 ML (OPHTHALMIC)	24.6%	ON	YES		
AZOPT (OPHTHALMIC)	3.1%	ON	YES		
BETOPTIC S (OPHTHALMIC)	1.5%	ON	YES		
LUMMIGAN 2.5ML (OPHTHALMIC)	9.5%	OFF	YES		
ISTALOL (OPHTHALMIC)	0.5%	ON	YES		
COMBIGAN (OPHTHALMIC)	2.1%	ON	YES		
XALATAN 2.5ML (OPHTHALMIC)	6.5%	ON	NO		
ALPHAGAN P (OPHTHALMIC)	10.0%	ON	YES		
TRAVATAN / TRAVATAN Z 5ML (OPHTHALMIC)	5.4%	ON	YES		
DORZOLAMIDE (OPHTHALMIC)	1.7%	ON	NO-GENERIC		
LUMIGAN 5ML (OPHTHALMIC)	4.6%	ON	YES		
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	8.9%	ON	NO-GENERIC		
LUMIGAN 7.5ML (OPHTHALMIC)	0.2%	ON	NO		

- The Committee made a motion to approve staff recommendations as presented.
 - Motion – Kevin Izard
 - Second - James Boblin
 - All members were in favor of the motion.